Results 171 to 180 of about 384,012 (260)

Real-World Outcomes Among Patients in the United States Receiving Tafamidis for Transthyretin Amyloid Cardiomyopathy. [PDF]

Cardiol Ther
Judge DP, Udall M, Rosen AM, Lamarre N, Nagelhout E, Dao HD, Maurer MS.   +6 more
europepmc   +1 more source

Clinical phenotype and prognosis of real-world patients with wild-type transthyretin amyloid cardiomyopathy treated with tafamidis. [PDF]

Eur J Heart Fail
Porcari A, Milani P, Longhi S, Cappelli F, Vagnarelli F, Aimo A, Cipriani A, Gardini E, Marazia S, Monda E, Tini G, Musumeci B, Serenelli M, Cantone A, Lofiego C, Marini M, Vergaro G, Foti G, Musca F, Tomasoni D, Bonacchi G, Colio F, Sinigiani G, De Michieli L, Sturdà F, Pozzan M, Gentile P, Carigi S, Bartolotti M, Sena G, Ruotolo I, Sanna GD, Zanoletti M, Canepa M, Di Marco M, D'Elia E, Di Bella G, Driussi M, Imazio M, Perfetto F, Biagini E, Limongelli G, Metra M, Emdin M, Merlini G, Perlini S, Merlo M, Palladini G, Sinagra G.   +48 more
europepmc   +1 more source

Wild Type Transthyretin Amyloid Cardiomyopathy Hidden Under Ablation-Refractory Atrial Arrhythmias and the Potential Contribution of Tafamidis in Rhythm Control. [PDF]

J Arrhythm
Horie T, Nagata Y, Nozato T, Miyazaki S, Ashikaga T.   +4 more
europepmc   +1 more source

A plain language review of the ATTRibute-CM study: efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. [PDF]

Future Cardiol
Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, Grogan M, Hanna M, Hoffman J, Masri A, Maurer MS, Nativi-Nicolau J, Obici L, Poulsen SH, Rockhold F, Shah KB, Soman P, Garg J, Chiswell K, Xu H, Cao X, Lystig T, Sinha U, Fox JC, ATTRibute-CM Investigators.   +24 more
europepmc   +1 more source

Current and Future Treatment Landscape of Transthyretin Amyloid Cardiomyopathy. [PDF]

Cardiol Ther
Margolin E, Stern LK, Argiro A, Rosenthal JL, Urey MA, Alexander KM.   +5 more
europepmc   +1 more source

Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: The HELIOS-B trial. [PDF]

Eur J Heart Fail
Sheikh A, Miao ZM, Claggett B, Garcia-Pavia P, Cappelli F, Aldinc E, Gillmore J, Solomon SD, Fontana M.   +8 more
europepmc   +1 more source

Population diversity of the genetically determined expression in human tissues and its implications in TTR amyloidosis [PDF]

core   +1 more source

Patient-Reported Outcomes in Older Adults With Transthyretin Amyloid Cardiomyopathy: When the Heart Isn't the Only Matter. [PDF]

JACC Adv
Zeis T, Chen V, Tang WHW, Goyal P, Hanna M, Damluji A, Martyn T.   +6 more
europepmc   +1 more source

Contemporary Oral Medication Use and Frequency in Patients with Transthyretin Amyloid Cardiomyopathy. [PDF]

Am J Cardiovasc Drugs
Dasgupta N, Poulsen SH, Emdin M, Ambardekar AV, Shah KB, Hennum L, Marwah R, Allison M, Shivanna P, Siddhanti S, Tamby JF, Falvey H, Grodin JL.   +12 more
europepmc   +1 more source

Incidental Cardiac Uptake on ^99mTc-HMDP Bone Scintigraphy in Oncology Patients: Two Cases of Transthyretin Amyloid Cardiomyopathy with Literature Review. [PDF]

Diseases
Matsuki N, Awaya T, Endo J, Kunimasa T, Gomi T, Okamoto Y, Hara H.   +6 more
europepmc   +1 more source